The Antidote: Inside the World of New Pharma
This is the Moneyball of the pharma world, the story of one drug company’s quest to transform the pharmaceutical industry and a deeply revealing look into a world where breakneck capitalism meets life-saving medicine.
IN THE ANTIDOTE, Barry Werth draws upon unprecedented inside reporting spanning more than two decades to provide a groundbreaking closeup of the upstart pharmaceutical company Vertex and the ferocious but indispensable world of Big Pharma that it inhabits.
In 1989, the charismatic Joshua Boger left Merck, then America’s most admired business, to found a drug company that would challenge industry giants and transform health care. Werth described the company’s tumultuous early days during the AIDS crisis in The Billion-Dollar Molecule, a celebrated classic of science and business journalism. Now he returns to tell a riveting story of Vertex’s bold endurance and eventual success.
The $325 billion-a-year pharmaceutical business is America’s toughest and one of its most profitable. It’s riskier and more rigorous at just about every stage than any other business, from the towering biological uncertainties inherent in its mission to treat disease; to the 30-to-1 failure rate in bringing out a successful medicine even after a molecule clears all the hurdles to get to human testing; to the multibillion-dollar cost of ramping up a successful product; to operating in the world’s most regulated industry, matched only by nuclear power.
Werth captures the full scope of Vertex’s twentyfive- year drive to deliver breakthrough medicines. At a time when America struggles to maintain its innovative edge, The Antidote is a powerful inside look at one of the most intriguing and important business stories of recent decades.
What people are saying - Write a review
THE ANTIDOTE: Inside the World of New PharmaUser Review - Kirkus
This follow-up to the author's book about upstart Vertex Pharmaceuticals (The Billion-Dollar Molecule: One Company's Quest for the Perfect Drug, 1994) details the firm's transition from boutique ... Read full review
Other editions - View all
ahead Alam Aldrich analysts announced antiviral approval biological biotech Bob Beall Bob Kauffman called cells cFTr clinical trials commercial company’s compounds cumbo cure cystic fibrosis Dendreon didn’t disease drug drugmaker earnings call emmens Genentech Gilead Glaxo going gonna guys hepatitis ian Smith incivek industry interviews investors Josh Boger Kalydeco Kauffman Ken Boger kinase knew Koppel labs late-stage launch Lilly liver look matt emmens medicine merck million molecule months mueller murcko novartis olson Partridge patients percent Peter mueller Pfizer Pharma pharmaceutical Pharmasset Phase Porges protease inhibitors protein recalls ribavirin Sachdev says Schering-Plough scientists shares strategy target telaprevir therapy there’s thing Thomson told treatment Tung Vertex Vertex Pharmaceuticals Vicki Sato Vioxx viral virus VrTX Wall Street weeks Weet what’s Wysenski Xconomy